that's the absolute worse-case scenario. AMAG has always had issues with adverse reactions. as long as it's an isolated batch, then it won't be another AFFY. regardless, the stock is overbought. it's skyrocketed the past several months on no real news. a 10% shave can be looked at as a correction. but i doubt too many will be buying until it's determined that this latest news was just a hiccup.